Policy & Regulation
AlzeCure reports positive Phase Ib results for Alzheimer's candidate ACD856
16 June 2026 - Swedish biotech company AlzeCure Pharma AB (Nasdaq First North Premier Growth Market:ALZCUR) on Tuesday reported positive results from the completed Phase Ib clinical study of ACD856, i...
Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026
16 June 2026 - Minghui Pharmaceutical, a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, announced on Monday the presenta...
Kalohexis presents dual MC3R/MC4R activation data at ENDO 2026
16 June 2026 - Clinical-stage biotechnology company Kalohexis Inc announced on Monday that data supporting dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) activation as a novel mechan...
Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease
16 June 2026 - Hillhurst Biopharmaceuticals Inc, a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products based on known inhaled therapeutics, announced on Mond...
Lonza and Antharis Therapeutics enter target-specific licence agreement
16 June 2026 - US biopharmaceutical company Antharis Therapeutics Inc and Lonza (SWX:LONN), a contract development and manufacturing organisation (CDMO) based in Switzerland, announced on Monday an ex...
Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes
16 June 2026 - Clinical-stage biotechnology company Halia Therapeutics Inc announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to ofirnoflast (HT-6184...